The University of Cambridge is making its first three investments into UoC spinouts through its new Enterprise Fund.
The University of Cambridge has made its first three investments in spinouts from the University through its Enterprise Fund for undisclosed amounts.
The three beneficiaries are startups Cambridge CMOS Sensors, Inotec AMD, and DefiniGEN.
Cambridge CMOS Sensors aims to provide mid-infrared emitters, and provide CMOS MEMS structure technology, which can be used in semiconductor sensors and nanosensors. It is based on technology developed by Cambridge’s Department of Engineering.
Inotec, spun out from the Department of Materials Science & Metallurgy, specialises in the treatment of debilitating wounds that can cause suffering for five years or more. Such wounds currently swallow up around 5% of healthcare budgets.
DefiniGEN specialises in stem cell research, and is looking to explore new opportunities for commercialisation in this area. The research DefiniGEN utilises allows scientists to generate stem cells by reprogramming cells from patients’ skin.
The fund, a combination of Cambridge’s Seed Enterprise Investment Scheme and Enterprise Investment Scheme (EIS) Fund, closed in September after being launched in May this year.
Cambridge has produced ten companies valued at more than $1bn, and two worth more than $10bn (ARM and Autonomy), making it one of the most successful technology clusters in Europe. The vast majority of these companies are either based on University research, founded by Cambridge graduates, or work directly with researchers.
